IL95300A - Process for the enzymatic preparation of esters of 1-castanospermine - Google Patents

Process for the enzymatic preparation of esters of 1-castanospermine

Info

Publication number: IL95300A
Authority: IL; Israel
Prior art keywords: halogen; methyl; optionally substituted; subtilisin; alkanoyl
Prior art date: 1989-08-08

Application number

IL9530090A

Other languages

English (en)

Hebrew (he)

Other versions

IL95300A0 (en

Original Assignee

Merrell Dow Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-08-08

Filing date

1990-08-06

Publication date

1994-10-21

1990-08-06 Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma

1991-06-30 Publication of IL95300A0 publication Critical patent/IL95300A0/xx

1994-10-21 Publication of IL95300A publication Critical patent/IL95300A/en

Links

238000000034 method Methods 0.000 title claims description 36
230000008569 process Effects 0.000 title claims description 19
238000002360 preparation method Methods 0.000 title claims description 15
230000002255 enzymatic effect Effects 0.000 title description 4
JDVVGAQPNNXQDW-TVNFTVLESA-N Castinospermine Chemical compound C1[C@H](O)[C@@H](O)[C@H](O)[C@H]2[C@@H](O)CCN21 JDVVGAQPNNXQDW-TVNFTVLESA-N 0.000 claims abstract description 25
JDVVGAQPNNXQDW-WCMLQCRESA-N Castanospermine Natural products O[C@H]1[C@@H](O)[C@H]2[C@@H](O)CCN2C[C@H]1O JDVVGAQPNNXQDW-WCMLQCRESA-N 0.000 claims abstract description 23
150000002148 esters Chemical class 0.000 claims abstract description 19
108090000787 Subtilisin Proteins 0.000 claims abstract description 15
-1 naphthalenecarbonyl Chemical group 0.000 claims description 30
150000001875 compounds Chemical class 0.000 claims description 29
229910052736 halogen Inorganic materials 0.000 claims description 21
150000002367 halogens Chemical class 0.000 claims description 21
238000006243 chemical reaction Methods 0.000 claims description 20
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 18
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 18
125000001589 carboacyl group Chemical group 0.000 claims description 11
150000002431 hydrogen Chemical group 0.000 claims description 10
229910052739 hydrogen Inorganic materials 0.000 claims description 10
239000001257 hydrogen Substances 0.000 claims description 10
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 9
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 8
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 8
125000000217 alkyl group Chemical group 0.000 claims description 6
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 6
229920002554 vinyl polymer Polymers 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
239000002904 solvent Substances 0.000 claims description 5
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 claims description 4
NKLCHDQGUHMCGL-UHFFFAOYSA-N cyclohexylidenemethanone Chemical group O=C=C1CCCCC1 NKLCHDQGUHMCGL-UHFFFAOYSA-N 0.000 claims description 4
125000003545 alkoxy group Chemical group 0.000 claims description 3
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 3
125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 claims 5
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 4
ORLCYMQZIPSODD-UHFFFAOYSA-N 1-chloro-2-[chloro(2,2,2-trichloroethoxy)phosphoryl]oxybenzene Chemical compound ClC1=CC=CC=C1OP(Cl)(=O)OCC(Cl)(Cl)Cl ORLCYMQZIPSODD-UHFFFAOYSA-N 0.000 claims 1
150000005690 diesters Chemical class 0.000 abstract description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
239000008103 glucose Substances 0.000 description 21
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
102000004190 Enzymes Human genes 0.000 description 11
108090000790 Enzymes Proteins 0.000 description 11
229940088598 enzyme Drugs 0.000 description 11
229930006000 Sucrose Natural products 0.000 description 10
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
239000005720 sucrose Substances 0.000 description 10
239000000203 mixture Substances 0.000 description 9
241001465754 Metazoa Species 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
WRMIVVLGWCQXNE-UHFFFAOYSA-N 2,2,2-trichloroethyl butanoate Chemical compound CCCC(=O)OCC(Cl)(Cl)Cl WRMIVVLGWCQXNE-UHFFFAOYSA-N 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical group C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
102000004882 Lipase Human genes 0.000 description 5
108090001060 Lipase Proteins 0.000 description 5
150000001720 carbohydrates Chemical class 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
239000000047 product Substances 0.000 description 5
241000146387 Chromobacterium viscosum Species 0.000 description 4
241000700159 Rattus Species 0.000 description 4
230000000694 effects Effects 0.000 description 4
230000002132 lysosomal effect Effects 0.000 description 4
229940049953 phenylacetate Drugs 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
239000004367 Lipase Substances 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 3
102400000472 Sucrase Human genes 0.000 description 3
101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 3
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
235000010233 benzoic acid Nutrition 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
239000003937 drug carrier Substances 0.000 description 3
238000001914 filtration Methods 0.000 description 3
201000001421 hyperglycemia Diseases 0.000 description 3
230000000968 intestinal effect Effects 0.000 description 3
229940040461 lipase Drugs 0.000 description 3
235000019421 lipase Nutrition 0.000 description 3
239000000463 material Substances 0.000 description 3
230000008018 melting Effects 0.000 description 3
238000002844 melting Methods 0.000 description 3
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
239000008363 phosphate buffer Substances 0.000 description 3
230000035484 reaction time Effects 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
JBTDFRNUVWFUGL-UHFFFAOYSA-N 3-aminopropyl carbamimidothioate;dihydrobromide Chemical compound Br.Br.NCCCSC(N)=N JBTDFRNUVWFUGL-UHFFFAOYSA-N 0.000 description 2
FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
150000001559 benzoic acids Chemical class 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
235000021310 complex sugar Nutrition 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000003345 hyperglycaemic effect Effects 0.000 description 2
239000012442 inert solvent Substances 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
230000003834 intracellular effect Effects 0.000 description 2
235000011073 invertase Nutrition 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
KDTCNLAFTGCTMM-UHFFFAOYSA-N 2,2,2-trifluoroethyl octanoate Chemical compound CCCCCCCC(=O)OCC(F)(F)F KDTCNLAFTGCTMM-UHFFFAOYSA-N 0.000 description 1
DKRNAIVMRLUUJH-UHFFFAOYSA-N 2,2-dichloroethyl butanoate Chemical compound CCCC(=O)OCC(Cl)Cl DKRNAIVMRLUUJH-UHFFFAOYSA-N 0.000 description 1
125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
JYPRYSVZABJWGS-UHFFFAOYSA-N 2-chloroethyl butanoate Chemical compound CCCC(=O)OCCCl JYPRYSVZABJWGS-UHFFFAOYSA-N 0.000 description 1
125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical compound OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
125000001216 2-naphthoyl group Chemical group C1=C(C=CC2=CC=CC=C12)C(=O)* 0.000 description 1
IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
241000193830 Bacillus <bacterium> Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
241001107116 Castanospermum australe Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010050375 Glucose 1-Dehydrogenase Proteins 0.000 description 1
102000004366 Glucosidases Human genes 0.000 description 1
108010056771 Glucosidases Proteins 0.000 description 1
102000005744 Glycoside Hydrolases Human genes 0.000 description 1
108010031186 Glycoside Hydrolases Proteins 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
102000019280 Pancreatic lipases Human genes 0.000 description 1
108050006759 Pancreatic lipases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
102100032491 Serine protease 1 Human genes 0.000 description 1
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
108010056079 Subtilisins Proteins 0.000 description 1
102000005158 Subtilisins Human genes 0.000 description 1
XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
229930013930 alkaloid Natural products 0.000 description 1
150000003797 alkaloid derivatives Chemical class 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000008901 benefit Effects 0.000 description 1
GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000001721 carbon Chemical group 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
239000012043 crude product Substances 0.000 description 1
125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
MSJMDZAOKORVFC-UAIGNFCESA-L disodium maleate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C/C([O-])=O MSJMDZAOKORVFC-UAIGNFCESA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000007911 effervescent powder Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
229940052296 esters of benzoic acid for local anesthesia Drugs 0.000 description 1
FPIQZBQZKBKLEI-UHFFFAOYSA-N ethyl 1-[[2-chloroethyl(nitroso)carbamoyl]amino]cyclohexane-1-carboxylate Chemical compound ClCCN(N=O)C(=O)NC1(C(=O)OCC)CCCCC1 FPIQZBQZKBKLEI-UHFFFAOYSA-N 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
244000144972 livestock Species 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
229940116369 pancreatic lipase Drugs 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
244000144977 poultry Species 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000004044 response Effects 0.000 description 1
230000001235 sensitizing effect Effects 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 description 1
241001478887 unidentified soil bacteria Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Wood Science & Technology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Enzymes And Modification Thereof (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

IL9530090A 1989-08-08 1990-08-06 Process for the enzymatic preparation of esters of 1-castanospermine IL95300A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/390,794 US4970317A (en)	1989-08-08	1989-08-08	Process for the preparation of castanospermine esters

Publications (2)

Publication Number	Publication Date
IL95300A0 IL95300A0 (en)	1991-06-30
IL95300A true IL95300A (en)	1994-10-21

Family

ID=23543967

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9530090A IL95300A (en)	1989-08-08	1990-08-06	Process for the enzymatic preparation of esters of 1-castanospermine

Country Status (15)

Country	Link
US (1)	US4970317A (de)
EP (1)	EP0412487B1 (de)
JP (1)	JP3019263B2 (de)
KR (1)	KR0167764B1 (de)
AT (1)	ATE116371T1 (de)
AU (1)	AU624013B2 (de)
CA (1)	CA2022576C (de)
DE (1)	DE69015499T2 (de)
DK (1)	DK0412487T3 (de)
ES (1)	ES2068957T3 (de)
GR (1)	GR3015396T3 (de)
HU (1)	HU209671B (de)
IE (1)	IE64971B1 (de)
IL (1)	IL95300A (de)
ZA (1)	ZA906098B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5066807A (en) *	1990-03-12	1991-11-19	Merrell Dow Pharmaceuticals Inc.	Process for the preparation of castanospermine
US5844102A (en) *	1994-07-07	1998-12-01	University Of Maryland Baltimore County	Glycohydrolase inhibitors, their preparation and use thereof
GB0110832D0 (en) *	2001-05-03	2001-06-27	Virogen Ltd	Antiviral compounds
MX2007003853A (es) *	2004-10-06	2007-11-21	Migenix Inc	Composiciones antivirales en combinacion que comprenden castanospermina y metodos de uso.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4952585A (en) *	1988-12-15	1990-08-28	Merrell Dow Pharmaceuticals Inc.	Castanospermine esters in the inhibition of tumor metastasis

1989
- 1989-08-08 US US07/390,794 patent/US4970317A/en not_active Expired - Lifetime
1990
- 1990-08-02 ZA ZA906098A patent/ZA906098B/xx unknown
- 1990-08-02 CA CA002022576A patent/CA2022576C/en not_active Expired - Lifetime
- 1990-08-03 AU AU60145/90A patent/AU624013B2/en not_active Expired
- 1990-08-06 DE DE69015499T patent/DE69015499T2/de not_active Expired - Lifetime
- 1990-08-06 ES ES90115107T patent/ES2068957T3/es not_active Expired - Lifetime
- 1990-08-06 EP EP90115107A patent/EP0412487B1/de not_active Expired - Lifetime
- 1990-08-06 AT AT90115107T patent/ATE116371T1/de not_active IP Right Cessation
- 1990-08-06 IL IL9530090A patent/IL95300A/en unknown
- 1990-08-06 DK DK90115107.6T patent/DK0412487T3/da active
- 1990-08-07 JP JP2207714A patent/JP3019263B2/ja not_active Expired - Lifetime
- 1990-08-07 IE IE285390A patent/IE64971B1/en not_active IP Right Cessation
- 1990-08-07 KR KR1019900012069A patent/KR0167764B1/ko not_active Expired - Lifetime
- 1990-08-07 HU HU904925A patent/HU209671B/hu unknown
1995
- 1995-03-13 GR GR950400549T patent/GR3015396T3/el unknown

Also Published As

Publication number	Publication date
EP0412487B1 (de)	1994-12-28
EP0412487A2 (de)	1991-02-13
CA2022576A1 (en)	1991-02-09
DK0412487T3 (da)	1995-02-20
DE69015499D1 (de)	1995-02-09
IL95300A0 (en)	1991-06-30
ZA906098B (en)	1991-05-29
AU624013B2 (en)	1992-05-28
KR0167764B1 (en)	1999-01-15
EP0412487A3 (en)	1991-05-29
HU209671B (en)	1994-10-28
ATE116371T1 (de)	1995-01-15
HU904925D0 (en)	1991-01-28
JP3019263B2 (ja)	2000-03-13
AU6014590A (en)	1991-02-14
US4970317A (en)	1990-11-13
IE902853A1 (en)	1991-02-27
ES2068957T3 (es)	1995-05-01
DE69015499T2 (de)	1995-05-11
GR3015396T3 (en)	1995-06-30
KR910004618A (ko)	1991-03-29
IE64971B1 (en)	1995-09-20
JPH0377883A (ja)	1991-04-03
HUT57271A (en)	1991-11-28
CA2022576C (en)	2001-05-01

Legal Events

Date	Code	Title	Description
1996-11-14	KB	Patent renewed
2000-11-21	KB	Patent renewed
2004-09-27	KB	Patent renewed
2006-09-05	HC	Change of name of proprietor(s)	Owner name: AVENTIS INC. Free format text: FORMER NAME:MERRELL PHARMACEUTICALS INC.

Publication	Publication Date	Title
NIWA et al.	1984	Novel glycosidase inhibitors, nojirimycin b and d-mannonic-δ-lactam isolation, structure determination and biological property
FI82836B (fi)	1991-01-15	Ny tetraklorraffinos och dess anvaendning vid framstaellning av sucralos.
Yoshikuni	1988	Inhibition of intestinal α-glucosidase activity and postprandial hyperglycemia by moranoline and its N-alkyl derivatives
CA2405066A1 (en)	2001-10-18	Percyquinnin, a process for its production and its use as a pharmaceutical
MXPA06011883A (es)	2006-12-14	42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y sintesis enzimatica de dos etapas de 42-ester de prolina-rapamicina con acido 2,2-bis(hidroximetil)propionico y 42-ester de rapamicina con acido 2,2-bis(hidroximetil)propionic
IE922132A1 (en)	1993-01-13	N-phenylthiourea derivatives and pharmaceutical use thereof
EP0412487B1 (de)	1994-12-28	Verfahren zur Herstellung von Castanosperminestern
EP0297534B1 (de)	1994-12-28	Castanosperminester und Glycoside
US4587256A (en)	1986-05-06	Novel thiazolidine derivatives
US4019960A (en)	1977-04-26	Process for the production of a saccharase inhibitor
KR850000318B1 (ko)	1985-03-20	비스글루코실 모라노린 유도체의 제조방법
Sariaslani et al.	1984	Formation of a reactive iminium derivative by enzymatic and chemical oxidations of 16-O-acetylvindoline
US5017563A (en)	1991-05-21	Castanospermine esters and glycosides
Duncan et al.	1958	Enzyme systems in marine algae. 2. Trans-α-glucosylation by extracts of Cladophora rupestris
Tanaka et al.	1994	Enzymatic hydrolysis of zenarestat 1‐O‐acylglucuronide
HUANG et al.	1984	Discovery, purification and characterization of the angiotensin converting enzyme inhibitor, L-681, 176, produced by Streptomyces sp. MA 5143a
US20020151581A1 (en)	2002-10-17	Glucose and lipid lowering compounds
WO1998042350A1 (en)	1998-10-01	Cholesterol lowering pharmaceutical composition
HU208528B (en)	1993-11-29	Process for producing pyridine-2,4- and 2.5-dicarboxylic acid-diamides and pharmaceutical compositions containing them
US4457941A (en)	1984-07-03	Use of pyrrolo-pyrrole in treating microvascular diseases associated with diabetes
Alan Davis et al.	1992	Comparison of the catalytic and inhibitory properties of Pachysolen tannophilus xylose reductase to rat lens aldose reductase
Cavestri et al.	1981	Antilipidemic activity of 4-oxo-functionalized ethyl 6-chlorochroman-2-carboxylate analogs and a related tricyclic lactone in three rat models
US4246275A (en)	1981-01-20	Antilipidemic para-[thienyl and furyl (alkyl or alkenyl)amino]-benzoic acid derivatives
EP0537921A2 (de)	1993-04-21	Enzymatische Synthese von chirale Alpha-Hydroxyketonen und deren Derivate
CA1336096C (en)	1995-06-27	Isolation of castanospermine and its use as an antidiabetic agent